FDA’s Social Media Messages Should Be Pretested, Risk Communication Advisors Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk Communication Advisory Committee members express support for FDA’s social media plans, but emphasize the importance of pretesting messages and studying the impact of agency efforts.
You may also be interested in...
MedWatch’s Patient-friendly Reporting Form Might Need An Overhaul
Promotion of the consumer MedWatch form needs to be improved if more physicians and consumers are to use it, FDA’s Risk Communications Advisory Committee says.
Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.